Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “positive” rating reiterated by equities research analysts at Leerink Swann in a research report issued on Tuesday, The Fly reports. They presently have a $552.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $580.00. Leerink Swann’s price target suggests a potential upside of 16.81% from the company’s current price.

Several other research firms have also weighed in on REGN. Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $375.00 to $484.00 in a research note on Friday, May 5th. Vetr lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 target price for the company. in a research note on Monday, May 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Piper Jaffray Companies boosted their target price on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research note on Tuesday, June 20th. Finally, BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $488.23.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.42% during midday trading on Tuesday, hitting $472.57. 378,469 shares of the company’s stock were exchanged. The stock has a market cap of $50.11 billion, a PE ratio of 47.41 and a beta of 1.66. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The stock’s 50 day moving average is $494.31 and its 200-day moving average is $428.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.82 earnings per share. Analysts predict that Regeneron Pharmaceuticals will post $14.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/15/leerink-swann-reiterates-positive-rating-for-regeneron-pharmaceuticals-inc-regn.html.

In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the completion of the sale, the chairman now directly owns 414,156 shares of the company’s stock, valued at approximately $189,741,429.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Sanofi purchased 136,050 shares of the business’s stock in a transaction on Friday, June 2nd. The stock was acquired at an average cost of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. Insiders sold 56,922 shares of company stock valued at $27,383,105 in the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Large investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.7% in the second quarter. Piedmont Investment Advisors LLC now owns 16,735 shares of the biopharmaceutical company’s stock worth $8,219,000 after buying an additional 276 shares during the last quarter. BB&T Investment Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $503,000. Intellectus Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 5.6% in the second quarter. Intellectus Partners LLC now owns 1,749 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 93 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $246,000. Finally, Nomura Holdings Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $3,209,000. 67.16% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.